Results: None of the single-dose regimens attained the target concentration; however, 50% of subjects in cohort D attained the target concentration. Variation in absorption and protein binding contributed to differences in concentrations. Pharyngeal fluid concentrations were negligible. The singledose regimens were well tolerated; the multidose regimen resulted in mild to moderate gastrointestinal symptoms in 43% of subjects.
Conclusions: None of the dosing regimens achieved the target concentration. However, the proposed theoretical target was extrapolated from penicillin data; there are no empirically derived pharmacokinetic/pharmacodynamic criteria for pharyngeal gonorrhea. Under alternative cephalosporin-specific therapeutic goals, the multidose regimen may be effective, although the absence of cefixime in pharyngeal fluid is concerning. A clinical trial evaluating efficacy and defining pharmacokinetic/pharmacodynamic outcomes may be warranted.
A ntimicrobial-resistant Neisseria gonorrhoeae is a major public health threat. 1 The Centers for Disease Control and Prevention removed cefixime from the recommended treatment guidelines for gonorrhea in 2012 2 because surveillance data showed a rapid increase in isolates with reduced susceptibility to cefixime, 3 and a number of case reports documented cefixime treatment failures. [4] [5] [6] Although in 2016, the proportion of surveilled isolates with reduced susceptibility to cefixime remained low, 7 this change left ceftriaxone, an injectable third-generation cephalosporin, as the primary recommended treatment of gonococcal infections. There are no oral first-line treatment options.
Reliance on an injectable antibiotic presents a number of practical problems. Many physicians' offices do not stock injectable drugs, and as an injection, use of ceftriaxone often requires a second visit, a barrier to treatment and an increased cost. In addition, expedited partner therapy for gonorrhea among heterosexuals 8 requires a fully oral treatment regimen, and elimination of such has the potential to diminish expedited partner therapy's use and effectiveness. 9 Between 1945 and 1989, as the minimum inhibitory concentrations (MICs) of penicillin G (PenG) for N. gonorrhoeae gradually rose, the effectiveness of penicillin was maintained by increasing the intramuscular dose from 50,000 units in 1945 to 4.2 million units in the 1970s. 10 On the basis of exposure-response data, 11 effective treatment was defined as a regimen that maintained total serum PenG levels more than 4 times the MIC for 7 to 10 hours. Because pharyngeal infections are more difficult to treat than anogenital infections, subsequent data recommended that treatment regimens should achieve total serum antibiotic levels more than 4 times the MIC 90 for more than 20 hours to cure gonococcal infection at the pharynx. 12 Recommended gonorrhea treatment regimens should be effective for infections at the pharynx because these asymptomatic infections often go undiagnosed, yet contribute to community transmission 13 and may facilitate the development of antimicrobial resistance.
14 However, there are no empirically derived pharyngeal pharmacokinetic/pharmacodynamic (PK/PD) data to inform this recommendation.
Given the need for an effective oral regimen in the face of rising cephalosporin resistance, we sought to define a cefixime dosing regimen that might effectively treat pharyngeal gonorrhea infections by isolates with an MIC of 0.5 μg/mL. We chose this MIC because it is one dilution higher than the Centers for Disease Control and Prevention's alert value MIC and thus is likely to both be clinically significant and circulate in the near future.
METHODS
We conducted a PK and safety study of high-and multidose cefixime. We aimed to identify a dosing regimen that would result in total serum cefixime concentrations of at least 2.0 μg/mL for more than 20 hours, which theoretically would be effective in treating pharyngeal infections by isolates with MICs of 0.5 μg/mL. Secondary objectives included (1) establishing the PK of each dosing regimen, (2) determining protein binding (i.e., free serum cefixime concentrations) in individual subjects, (3) quantifying the concentration of cefixime in pharyngeal fluid (cohorts C and D), and (4) assessing the safety and tolerability of each treatment regimen.
Twenty-five adults who met the criteria of the National Institutes of Health Healthy Volunteer policy 15 were enrolled in 4 cohorts of a phase 1, open-label, nonrandomized, dose and frequency escalation study. Successive cohorts of 6 subjects each received oral doses of 400 mg (cohort A), 800 mg (cohort B), 1200 mg (cohort C), or 800 mg given every 8 hours for 3 doses (cohort D; total dose 2400 mg).
Subjects
Volunteers were healthy men and women between the ages of 18 and 45 years with a body mass index of less than 35 kg/m 2 . Exclusion criteria included histories of gastrointestinal diseases or surgeries that might alter drug absorption, allergic reactions to cephalosporins and/or penicillin, and renal impairment which might prolong half-life. Female subjects were screened for pregnancy and required to use 2 forms of contraception during the study period and for 30 days thereafter. Inclusion criteria included normal electrocardiogram, hematology, chemistry, liver function, coagulation values, and urinalysis and negative urine toxicology. Subjects were asked to refrain from using any prescription or over-the-counter medications for at least 7 days (5 half-lives) before dosing, with the exception of oral contraceptives.
Study Design
The study (clinicaltrials.gov NCT01949363) was conducted at the Johns Hopkins Bayview Clinical Trials (JHBMC) Unit between December 17, 2013, and December 1, 2014. It was reviewed and approved by the institutional review board of Johns Hopkins University. Cefixime was manufactured by Lupin Pharmaceuticals, Inc, Mumbai, India, and was supplied in 400-mg tablets. Study drug was maintained in the Research Pharmacy at JHBMC and dispensed by the research pharmacist.
Subjects were screened within 4 weeks of enrollment, and during study intervention, they were admitted to an inpatient unit for dosing, blood and pharyngeal fluid collection, and safety monitoring. Dosing followed a 6-hour fast; subjects were permitted to eat 3 hours after dosing and to drink water ad libitum. A predose blood sample was obtained from all subjects in all cohorts. 
Cefixime Concentration Measurement
The Pediatric Pharmacology Research Center at the University of Toledo processed the samples that were received on dry ice from JHBMC and stored at −70°C until analyzed. Pharyngeal swabs were thawed and reweighed. The difference between the 2 weights was the amount of pharyngeal fluid collected. Serum and pharyngeal fluid cefixime concentrations were measured using validated liquid chromatography-tandem mass spectrometry techniques that used cephalexin as the internal standard 16 (detailed methods available in Supplemental Data, http://links.lww. com/OLQ/A262).
PK Analysis
We generated serum cefixime time-concentration plots for individual subjects and cohort means using SAS (Cary, NC). The following serum PK parameters were estimated using noncompartmental techniques with Phoenix WinNonlin, version 6.3 (Pharsight Corp, Mountain View, CA): C max (maximal plasma concentration), T max (time to maximal concentration), t 1/2 (elimination half-life), AUC 0-τ (area under the plasma drug concentration vs. time curve, to last measurable concentration), AUC 0-inf (area under the plasma drug concentration vs. time curve, to infinity), K e (elimination rate constant), Cl/F (apparent clearance), V/F (apparent volume of distribution).
Because cohort D concentrations for the first 24 hours resulted from multiple doses, as opposed to the single doses in cohorts A to C, comparable PK parameters could not be estimated using the same methods. To produce parameters that could be compared with those of cohort B, half-life, terminal slope, and concentration at 24 hours (assuming no additional doses) were calculated using standard formulas. AUC 0-τ could then be estimated using WinNonlin:
where N(t) is the unknown concentration at time t; N(0) is the starting concentration; t is the elapsed time; t 1/2 is the half-life; ln is the natural log; and Cl/F, V d /F, and AUC 0-∞ were not able to be estimated using these methods. Free cefixime concentrations were measured at 3 time points for each subject. The mean and range of values, as well as the percent free drug, were calculated for each time point.
Safety Analyses
Routine laboratory studies (including hematology, chemistry, liver function tests, coagulation panel, urinalysis; electrocardiogram; vital signs; and targeted physical examinations) were performed at 24, 48, and 168 hours. Subjects recorded symptoms on a symptom diary card throughout the study period. These were reviewed with a study physician at 24, 48, and 168 hours. All adverse events (AEs) were evaluated by a study physician to grade severity and relationship to study drug. Severity was graded with use of standard National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases criteria. An independent safety monitoring committee reviewed all AE data after cohort C and again after cohort D.
RESULTS

Study Participants
Each of the six subjects were enrolled in each cohorts (A-C) and 7 were enrolled in cohort D. One subject in cohort D was withdrawn after completing dosing because of a positive urine toxicology result (mislabeled on the laboratory report). He was included in safety analyses but not in PK analyses. No subject discontinued the study. Overall, the study population was young, and predominately male (n = 17; 71%) and African American (n = 15; 62.5%). Figure 1 depicts the mean and SD total serum cefixime concentration versus time curves for each of the 4 cohorts; corresponding PK parameters are listed in Table 1 . At each dose, there was wide variability. The concentration versus time curves for the 400-and 800-mg dose regimens are similar to those reported previously. 17 Cohorts A, B, and C demonstrate that the C max , Cl/F, and t 1/2 are independent of dose; however, drug exposure is not dose proportional. C max and AUC begin to plateau at single doses of 800 mg resulting in little impact of increasing dose on the time above the target. Cohorts A to C achieved approximately 8, 10, and 11 hours above the target concentration, respectively (Fig. 1) .
Pharmacokinetics
The multidose cohort demonstrated a similar PK pattern. C max was analogous to the value seen with a single 800-mg dose without any apparent drug accumulation upon subsequent dosing, and the calculated AUC 0-τ was indistinguishable from that calculated for cohort B. The elimination half-life showed greater interindividual variability, but with the exception of one outlier, the mean was comparable to that seen in the single-dose cohorts.
Serum-Free Cefixime Concentrations
Serum-free cefixime concentrations (Fig. 2) showed a similar protein-binding pattern in the single-dose cohorts. Approximately 1 hour after dosing, the concentration of free cefixime was lowest, peaking approximately 4 hours after dosing, followed by a gradual decline to the 1-hour level by 12 to 13 hours. Cohort D showed a time-dependent decrease in serum-free cefixime concentrations. Free drug concentrations seemed to decline with increasing dose (Fig. 3 ) and overall ranged from just greater than 20% of total serum concentrations for some subjects in cohort D to greater than 95% for some subjects in cohorts A to C.
Pharyngeal Fluid Concentrations
Seven pharyngeal fluid samples from cohort C had insufficient fluid for analysis, and only 2 (9%) of the remaining 23 had measurable cefixime concentrations above the lower limit of quantitation of the assay (10 ng/mL). Both concentrations were less than 50 ng/mL. One cohort D sample had insufficient fluid for analysis, and all other 29 samples were below the lower limit of quantitation.
Therapeutic Target
None of the single-dose regimens resulted in total serum cefixime concentrations greater than 2.0 μg/mL for more than 20 hours in all subjects. Visual inspection of the summary serum concentration versus time curve for the multidose regimen (cohort D, Fig. 1D ) shows that the mean value achieved this target, albeit with wide interindividual variation. The cohort D average (SD) consecutive time greater than 2.0 μg/mL was 22.3 hours, whereas the average total time greater than 2.0 μg/mL was slightly higher at 25.2 (10.3; range, 11-35 hours). The time greater than 2.0 μg/mL varied by individual from 8.5 to 35 hours. Only 3 (50%) of 6 subjects had total serum cefixime concentrations greater than 2.0 μg/mL for more than 20 hours consecutively, and 4 (66.7%) of 6 subjects' total serum cefixime concentration exceeded greater than 2.0 μg/mL for a total time of more than 20 hours.
Safety and Tolerability
Overall, 23 subjects (92.2%) reported or were found to have an AE, but in only 20 (80%) subjects, either AEs were deemed to be related to study drug or the study drug could not be excluded (Table 2 ). There were no severe or life-threatening AEs. The most commonly reported symptoms were gastrointestinal, with 24% (n = 6) of the study population complaining of flatulence and nausea and 20% (n = 5) reporting diarrhea. These complaints were reported more frequently by the cohort D subjects. Most events were mild in severity. Five subjects reported moderate AEs: 2 in cohort B experienced headaches, 1 in cohort D had increased liver transaminases, and 1 in cohort A reported hematuria. Seven subjects experienced moderate laboratory abnormalities across the 4 cohorts. All were considered not clinically significant except for elevated transaminases in a cohort D subject on day 7, which resolved without intervention.
DISCUSSION
There is an urgent need for effective oral antibiotic treatment of N. gonorrhoeae. We aimed to determine whether an alternative dosing strategy of cefixime could treat potentially cephalosporinresistant pharyngeal gonococcal infections. The study was designed under the assumption that, similar to PenG, clinical cure of anogenital gonococcal infections required total serum concentrations 4Â above the organism's MIC for 7 to 10 hours, 11 and treatment of pharyngeal infections would require concentrations at least 4Â the MIC for at least 20 hours. 12 Thus, to treat infections caused by N. gonorrhoeae with cefixime MIC of 0.5 μg/mL, the target was defined as a total cefixime concentration of at least 2.0 μg/mL for 20 hours. None of the single-dose regimens resulted in cefixime plasma levels that met our prespecified target concentration (Fig. 1) , and only half of the subjects in the multidose regimen achieved our target.
Cefixime pharmacokinetics of 400-and 800-mg doses were indistinguishable from those reported previously. 18, 19 Pharmacokinetics in subjects who received the 1200-mg single dose showed preservation of the parameter estimates for drug elimination (e.g., t 1/2 and Cl/F; Table 1 ). The multidose regimen resulted in target attainment in half of the subjects (Fig. 1D) . Although the pharmacokinetics of this regimen were more complex, those parameter estimates related to drug elimination were preserved.
Cefixime exposure was not dose proportional. This was not unexpected because studies done during the drug's development noted that it had several distinctive characteristics. The C max plateau at higher doses is a function of the absorption kinetics. 17, 20 Bioavailability of 200-and 400-mg doses is reported to be 40% to 50% and variable. When cefixime absorption kinetics at standard doses were examined in detail, the observed data best fit a rather complex Michaelis-Menten model with an "absorption window" (M-M Δt). 20 Clinically, this is reflected in an apparent saturation of drug absorption with increasing doses. This phenomenon is seen with other orally administered β-lactam agents, such as amoxicillin, that have decreasing bioavailability with increasing doses. 21 The phenomenon is confounded further with multidose cefixime. Its poor absorption would leave drug from the previous dose(s) in the intestinal lumen at the time of the subsequent dose, which would result in further decreased bioavailability, as compared with the expected values.
Although both β-lactams, PenG and cefixime are chemically distinct and have quantitative differences in absorption, distribution, and elimination. Cefixime is moderately protein bound in serum, 18, 19 whereas protein binding of PenG is virtually nonexistent. In our study, the time-dependent protein binding of cefixime was assessed in individual subjects, whereas the average serum protein binding was 62%, consistent with previous reports 18 ; individual subjects had time-dependent and dosedependent differences in free drug concentrations. These differences amplified the interindividual differences between total and active (unbound) drug concentrations. The observations that most reported cefixime failures have occurred in patients infected with highly susceptible organisms 22 may reflect the interindividual impact of some of the PK idiosyncrasies of the drug.
Our target, greater than 2.0 μg/mL for 20 hours, was extrapolated from exposure-response data for PenG and urethral gonorrhea. However, the differences in protein binding between PenG and cefixime are substantial. The evidence supporting PK criteria for defining clinical efficacy for either drug class is very limited, and no single criteria are universally accepted. Chisholm et al. 23 estimated the potential value of different gonorrhea treatments assuming that therapy would be effective if free cephalosporin levels exceeded the MIC for 24 hours. Using the criteria of Chisholm et al., it seems that 800 mg every 8 hours for 3 doses would meet that goal. Other investigators have assumed that a treatment would be bactericidal and likely effective if free drug exceeds the MIC for approximately 65% of the dosing 24 a threshold that our multidose cefixime regimen would also achieve.
Newer PK theory posits that to be effective, an antibiotic must reach the site of infection in unbound concentrations that are antimicrobially important. We hoped to identify a regimen that would reliably eradicate N. gonorrhoeae with cefixime MIC of 0.5 μg/mL from the oropharynx, but we detected negligible cefixime concentrations in oropharyngeal fluid and only among subject receiving 1200 mg. The absence of cefixime in oropharyngeal fluid after the 400-, 800-, and 800-mg doses every 8 hours was not expected because this drug has long been used to treat pharyngeal gonococcal infections and seems to be at least partially effective. 22, 25, 26 Mroczkowski et al. 27 reported that 400 mg of cefixime cured 11 of 16 persons with pharyngeal gonorrhea with tests of cure 5 to 10 days after treatment. Others have estimated the efficacy of a single 400-mg dose at 70% to 80%. Gratrix et al., 22 who reported an efficacy of 70% (38/54; tests of cure 7-34 days) among persons treated between 2008 and 2011, reported that treatment failures were not related to cefixime MICs and that an 800-mg dose was not superior to 400 mg. Although these studies suggest that cefixime is at least somewhat effective in the treatment of pharyngeal gonorrhea caused by susceptible gonococci, none of these studies included an untreated control group, and it is possible that at least some persons cured with antibiotics spontaneously cleared their infections. Relatively small previous studies have found that oropharyngeal gonococcal infections are self-limited [28] [29] [30] and spontaneously clear without therapy by 60 days after detection. 28, 29 Chow et al 30 reported that 19 of 33 infections cleared 3 to 14 days after no treatment. In the context of an undefined duration of untreated pharyngeal gonococcal and at least some apparent efficacy for pharyngeal gonococcal infection, it is difficult to interpret the lack of cefixime in pharyngeal fluid in this study.
Taken together, our findings highlight the many uncertainties surrounding the natural history, pathophysiology, and treatment of pharyngeal gonococcal infections. These infections are clearly more difficult to treat than genital tract infections, 12 likely due to some combination of relatively low drug levels as the site of infection and the poor bioavailability of commonly used drugs, like cephalosporins, a problem that also affects the treatment of pharyngeal carriage of Neisseria meningitidis.
31
Multidose intramuscular PenG failed to eradicate pharyngeal carriage of N. meningitidis and was abandoned for chemoprophylaxis of high-risk populations, 31 and high protein binding of ceftriaxone in tonsillar tissue was found to explain the poor efficacy of a single 500-mg dose of this cephalosporin in curing group A streptococcal tonsillopharyngitis. 32 In conclusion, single-dose cefixime was well tolerated, including the 1200-mg dose. Although the 800-mg dose every 8 hours met our target in half of the subjects, it occasioned mild gastrointestinal complaints in 43% of subjects. Although this dosing regimen did not achieve our target, the observed drug levels met some other widely used PK targets for drug efficacy. 23, 24 Considering cefixime in this context, it is likely that the 800-mg singledose regimen would effectively treat anogenital infections caused by most organisms, and that 800 mg every 8 hours for 3 doses may cure pharyngeal infection with gonococcal isolates with MIC of 0.5 μg/mL or less. However, only a clinical trial of persons infected with N. gonorrhoeae with elevated MICs can truly answer that question.
